Form 4: Edwards Lifesciences Executive Reports Stock Grant and Tax Withholding

Catherine M. Szyman, CVP at Edwards Lifesciences, reports acquisition of restricted stock units and disposition of shares for tax withholding.

Summary

• Catherine M. Szyman, a CVP at Edwards Lifesciences, filed a Form 4 detailing changes in beneficial ownership.
• On May 7, 2024, Szyman acquired 32,025 shares of common stock as restricted stock units (RSUs) granted under the company's Long-Term Stock Incentive Compensation Program.
• These RSUs will vest in four equal annual installments, starting one year after the grant date.
• Also on May 7, 2024, Szyman disposed of 609 shares of common stock at $85.09 per share to cover tax obligations.
• Following these transactions, Szyman beneficially owns 76,992.4373 shares of Edwards Lifesciences common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects routine executive compensation and tax obligations.

Positives

• The grant of restricted stock units aligns the executive's interests with the long-term performance of the company.

Future Outlook

The restricted stock units will vest over the next four years, incentivizing continued performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates standard executive compensation practices.

Comparison to Industry Standards

• Stock grants are a common form of executive compensation in the medical device industry, aligning executive incentives with shareholder value.
• Companies like Medtronic and Abbott also utilize stock grants as part of their executive compensation packages.
• The vesting schedule of four equal annual installments is a typical vesting structure.

Stakeholder Impact

• The stock grant aligns executive interests with shareholder value.
• Tax withholding impacts the executive's personal finances.

Key Dates